GLOBUS MEDICAL INC CLASS A (GMED)
Sector: Health Care
2026 Annual Meeting Analysis
GLOBUS MEDICAL INC CLASS A · Meeting: June 3, 2026
Directors FOR
2
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Two Class II Directors
Douglas joined the board in December 2019 (over 24 months ago), but GMED's 3-year price return of +63.5% outperforms the peer group median by +96.9 percentage points, which is well above the 65-point threshold needed to trigger a vote against for companies with strong positive returns, so no TSR concern applies; he has relevant medical device operating experience and serves as an audit committee financial expert with no overboarding or attendance issues disclosed.
Pfeil has served as a director only since July 2025, which is less than 24 months, making him exempt from the TSR trigger under policy; he is the newly appointed CEO with deep financial and operational expertise in the medical device industry and no overboarding or attendance concerns.
Both Class II director nominees pass all policy screens: GMED's 3-year total shareholder return of +63.5% outperforms the company-disclosed compensation peer group median by approximately +96.9 percentage points (well above the 65-point trigger threshold for strong-positive-TSR companies), no overboarding or attendance issues are disclosed, and each nominee brings relevant industry or financial expertise.
Say on Pay
✓ FORCEO
Keith W. Pfeil
Total Comp
$4,400,159
Prior Support
98%%
The prior year say-on-pay vote received overwhelming support at 98%, well above the 70% threshold that would require a response. CEO Keith Pfeil's total reported compensation of $4,400,159 is reasonable for a newly appointed CEO at a $12.8 billion medical device company, and the company's stock has dramatically outperformed both its compensation peer group (by +96.9 percentage points over three years) and the medical device benchmark IHI — iShares US Medical Devices ETF (by +68.1 percentage points over three years), demonstrating strong pay-for-performance alignment. The compensation program relies primarily on time-vested stock options (which tie executive outcomes directly to share price) and a revenue-based cash bonus, providing meaningful variable pay linkage to company results.
Auditor Ratification
✓ FORAuditor
Deloitte & Touche LLP
Tenure
9 yrs
Audit Fees
$3,041,899
Non-Audit Fees
$1,895
Deloitte has audited Globus Medical since April 2017 (approximately 9 years), well below the 25-year tenure threshold; non-audit fees of $1,895 represent less than 0.1% of total audit fees of $3,041,899, far below the 50% threshold that would raise independence concerns; Deloitte is a Big 4 firm appropriate for a $12.8 billion company, and no material restatements are disclosed.
Overall Assessment
The 2026 Globus Medical annual meeting ballot is straightforward: both Class II director nominees pass all policy screens given the company's exceptional stock outperformance versus peers and IHI — iShares US Medical Devices ETF over three years, the auditor ratification presents no independence concerns with de minimis non-audit fees and a nine-year tenure, and the say-on-pay proposal is supported by strong prior-year backing, reasonable CEO pay, and clear pay-for-performance alignment. No stockholder proposals appear on this ballot, and the equity plan amendment (Proposal 2) falls outside the current scope of this policy.
Compensation Peer Group
15 companies disclosed in 2026 proxy filing